Clinical, functional and health-related quality of life correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis: a cross-sectional survey
- PMID: 24587375
- PMCID: PMC3938731
- DOI: 10.1371/journal.pone.0090484
Clinical, functional and health-related quality of life correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis: a cross-sectional survey
Abstract
Objectives: To identify clinical, functional and health-related quality of life (HRQoL) correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis (SSc).
Methods: Three-hundred-and-eighty-one patients fulfilling the American College of Rheumatology and/or the Leroy and Medsger criteria for SSc were assessed for visceral involvement, disability and HRQoL (assessed by SF-36). Clinically significant symptoms of anxiety and depression were evaluated with the Hospital Anxiety Depression Scale (HAD) (defined cut-off≥8).
Results: 9.2% the patients had limited SSc, 50.5% limited cutaneous SSc (lcSSc), and 40.3% diffuse cutaneous SSc (dcSSc). Overall, 40.4% and 58.8% of the patients had clinically significant symptoms of depression and anxiety, respectively. Compared to patients without clinically significant symptoms of depression, patients with clinically significant symptoms of depression had poorer health status, HRQoL mental and physical component, and greater global disability, hand disability and aesthetic impairment. Compared to patients without clinically significant symptoms of anxiety, patients with clinically significant symptoms of anxiety had poorer SF-36 mental and physical component scores. On multivariable analysis, excluding mental component score of SF-36, variables independently associated with clinically significant symptoms of depression and anxiety were global disability and physical component of SF-36, plus female gender for clinically significant symptoms of anxiety only. Remarkably, patients with and without clinically significant psychiatric symptoms were comparable for all disease-related clinical features assessed.
Conclusion: High levels of clinically significant symptoms of anxiety and depression are observed among SSc patients. Clinically significant psychiatric symptoms are rather associated with increased disability and altered HRQoL, than with disease-specific organ manifestations.
Conflict of interest statement
Similar articles
-
Factors associated with quality of life in systemic sclerosis: a cross-sectional study.Qual Life Res. 2019 Dec;28(12):3347-3354. doi: 10.1007/s11136-019-02284-9. Epub 2019 Sep 3. Qual Life Res. 2019. PMID: 31482431 Free PMC article.
-
Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study.Arthritis Res Ther. 2019 Feb 15;21(1):61. doi: 10.1186/s13075-019-1842-x. Arthritis Res Ther. 2019. PMID: 30770765 Free PMC article. Clinical Trial.
-
Association of gender with clinical expression, quality of life, disability, and depression and anxiety in patients with systemic sclerosis.PLoS One. 2011 Mar 9;6(3):e17551. doi: 10.1371/journal.pone.0017551. PLoS One. 2011. PMID: 21408076 Free PMC article.
-
The impact of systemic sclerosis on health-related quality of life assessed by SF-36: A systematic review and meta-analysis.Int J Rheum Dis. 2018 Nov;21(11):1884-1893. doi: 10.1111/1756-185X.13438. Epub 2018 Nov 14. Int J Rheum Dis. 2018. PMID: 30428506
-
Approach to Systemic Sclerosis Patient Assessment: How Does Patient Subsetting Help?Rheum Dis Clin North Am. 2023 May;49(2):193-210. doi: 10.1016/j.rdc.2023.01.001. Epub 2023 Mar 1. Rheum Dis Clin North Am. 2023. PMID: 37028831 Review.
Cited by
-
Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis.Arch Rheumatol. 2019 Jan 28;34(3):253-261. doi: 10.5606/ArchRheumatol.2019.7111. eCollection 2019 Sep. Arch Rheumatol. 2019. PMID: 31598589 Free PMC article.
-
Patient perception of disease burden in diffuse cutaneous systemic sclerosis.J Scleroderma Relat Disord. 2020 Feb;5(1):66-76. doi: 10.1177/2397198319866615. Epub 2019 Aug 21. J Scleroderma Relat Disord. 2020. PMID: 35382406 Free PMC article.
-
The diagnostic value of trichoscopy in systemic sclerosis.J Dermatol Case Rep. 2016 Nov 13;10(2):21-25. doi: 10.3315/jdcr.2016.1225. eCollection 2016 Nov 13. J Dermatol Case Rep. 2016. PMID: 27900061 Free PMC article.
-
Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS).J Scleroderma Relat Disord. 2021 Jun;6(2):146-153. doi: 10.1177/2397198320957552. Epub 2020 Sep 17. J Scleroderma Relat Disord. 2021. PMID: 34222671 Free PMC article.
-
Psychological and self-management support for people with vasculitis or connective tissue diseases: UK health professionals' perspectives.Rheumatol Adv Pract. 2020 May 27;4(2):rkaa016. doi: 10.1093/rap/rkaa016. eCollection 2020. Rheumatol Adv Pract. 2020. PMID: 32968704 Free PMC article.
References
-
- Tamby MC, Chanseaud Y, Guillevin L, Mouthon L (2003) New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2: 152–157. - PubMed
-
- Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, et al. (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52: 3792–3800. - PubMed
-
- Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43: 2437–2444. - PubMed
-
- Poole JL, Steen VD (1991) The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 4: 27–31. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical